TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07397611: Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Sponsor: Dana-Farber Cancer Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07397611 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07397611 Rescue Dossier →